
==== Front
Turk Patoloji Derg
Turk Patoloji Derg
Turk Patoloji Derg
Turkish Journal of Pathology
1018-5615
1309-5730
1018-5615
Federation of Turkish Pathology Societies Ankara, Turkey

39115365
10.5146/tjpath.2024.13650
Original Article
Prevalence of Papillary Thyroid Carcinoma is Significantly Higher in Graves Disease with Synchronous Thyroid Nodules*
Kefeli Mehmet *
Gucer Hasan
Durmuş Elif Tutku
Atmaca Aysegul
Colak Ramis
Mete Ozgur
Department of Pathology, Ondokuz Mayis University, Samsun, Türkiye
Department of Pathology, Recep Tayyip Erdogan University, Rize, Türkiye
Department of Endocrinology and Metabolism, Ondokuz Mayis University, Samsun, Türkiye
Endocrine Oncology Site Group, The Princess Margaret Cancer Centre, Toronto, On, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, On, Canada; Department of Pathology, University Health Network, Toronto, On, Canada
* E-mail: mehmetkefeli@gmail.com
Concept: OM, MK, HG, ETD, AA, RC, Design: OM, MK, HG, ETD, Supervision: OM, Data collection and/or processing: MK, HG, ETD, AA, RC, Analysis and/or interpretation: MK, HG, ETD, AA, RC, Literature search: MK, ETD, OM, Writing: MK, ETD, OM, Approval: MK, HG, ETD, AA, RC, OM.

2024
02 9 2024
40 3 190195
24 7 2024
29 7 2024
Copyright © 2024 The Author(s).
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ This is an open-access article published by Federation of Turkish Pathology Societies under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.
Objective: The association between autoimmunity-related tissue injury and thyroid cancer development remains an area of interest. Evidence suggests that patients with Graves disease (GD) may have an elevated risk for differentiated thyroid cancer. Multicenter studies are needed to gain insight into the correlates of papillary thyroid carcinoma (PTC) identified in this particular group of patients. This study aimed to investigate the prevalence of PTC and synchronous thyroid nodules in thyroidectomy specimens from GD patients in an endemic goiter region.

Material and Methods: A retrospective review of institutional pathology records at two tertiary care centers identified 237 surgically treated patients with GD. Patients were categorized as having nodular Graves disease (N-GD) if synchronous nodular thyroid was identified by ultrasonography, while those without synchronous thyroid nodules were categorized as non-nodular or simple Graves disease (S-GD). The prevalence of PTC, histopathological correlates, and demographic characteristics were recorded and compared between groups N-GD and S-GD.

Results: One hundred thirty-one and 106 patients were assigned to N-GD and S-GD, respectively. The mean age was significantly higher in N-GD (mean 45.52 years) compared to S-GD (mean 35.18 years) (p<0.001). The overall frequency of PTC was 36.3% (86/237) in the entire cohort. PTC was identified in 48.1% (63/131) of N-GD and 21.7% (23/106) of S-GD (p<0.001). Subcentimeter tumors constituted the majority of cases in both groups (76.2% in N-GD and 82.6% in S-GD) (p>0.05). The group of S-GD was enriched in BRAF-like PTCs, whereas N-GD had equal distribution for RAS- and BRAF-like tumors.

Conclusion: This study underscores that the majority of PTCs encountered in GD were enriched in low-risk subcentimeter PTCs with a prevalence that varies depending on the presence of underlying nodular thyroid tissue.

Graves disease
Papillary thyroid carcinoma
Thyroid carcinoma
BRAF-like
RAS-like
==== Body
pmcINTRODUCTION

Graves disease (GD), also known as diffuse hyperplasia, is an autoimmune endocrine disease characterized by excessive production of thyroid hormones and diffuse enlargement of the thyroid gland (1). The estimated prevalence of GD in the US population is approximately 0.4%-1% (2,3). The pathogenesis of GD involves the production of stimulating TSHR autoantibodies and the presence of immune cells reactive to the TSHR antigen. Excessive autoantibody production leads to TSHR activation, resulting in increased thyroid hormone synthesis, follicular cell proliferation, and diffuse gland enlargement. This process is accompanied by a complex interaction between T lymphocytes and thyroid follicular cells, which leads to tissue injury (4,5).

The role of autoimmunity-related tissue injury and thyroid cancer development is an area of interest. Studies suggested that patients with GD may have an increased risk of differentiated thyroid cancer, with incidence rates ranging from 2-33.7% in case series (6–13). While thyroid glands are usually diffusely enlarged in GD, nodules can also be present and detected through palpation or imaging studies (14–17). Some series have reported that the follicular cell-derived thyroid carcinoma incidence is more frequently in thyroid nodular lesions when compared to incidental follicular cell-derived thyroid carcinoma in patients with GD without nodules (6–8,18–20).

Multicenter studies are much needed to gain insights into the correlates of papillary thyroid carcinoma (PTC) identified in this particular group of patients. For this reason, the current study investigated the prevalence of PTC and synchronous thyroid nodules in thyroidectomy specimens of GD patients from an endemic goiter region.

MATERIAL and METHODS

A retrospective review of institutional pathology records at two tertiary care centers identified 237 surgically treated patients with GD who underwent thyroidectomy between 2010 and 2019 at Ondokuz Mayis University (n = 139) and Recep Tayyip Erdogan University (n = 98). Institutional REB (research ethics board) approvals were obtained. In the process of data collection, the following information was recorded: demographic data of the patients, medical histories and treatments, results of neck ultrasonography (US) (presence or absence of thyroid nodules), thyroid scintigraphy/radioactive iodine uptake, measurements of thyroid function [levels of free triiodothyronine (fT3), free thyroxine (fT4), and thyroid-stimulating hormone (TSH)], thyroid autoantibodies (anti-thyroglobulin, antithyroid peroxidase, and thyroid-stimulating hormone receptor antibodies), indications and notes for all operations, and histopathological results. The diagnoses of GD were made based on relevant medical histories and signs of hyperthyroidism, laboratory findings of reduced TSH with elevations of fT3/fT4, identification of thyroid autoantibodies in serum, and increased uptake of radioactive iodine or diffuse uptake according to thyroid scintigraphy at the time of admission. Additional assessment also included the search for ophthalmopathy, and colored-flow or power Doppler US was performed as necessary to confirm the diagnosis. Observations, such as hypoechogenicity and diffuse thyroid enlargement, were noted on US and were considered along with observations from power Doppler US (21). None of the participating patients had undergone radioiodine therapy or external irradiation of the neck. Two patient groups were included in the study, with participants divided based on the US findings. Patients were grouped as having N-GD when a coexistent nodular thyroid was identified by thyroid ultrasonography, and those without synchronous thyroid nodules were grouped as simple GD (S-GD). The prevalence of PTC and its histopathological and demographic correlations were compared between the two groups. PTCs with exclusive follicular architecture were assigned to RAS-like PTCs whereas tumors with classic architecture and/or special cytomorphology (e.g., tall cell) were assigned to BRAF-like PTCs. Tumors with oncocytic and clear cell change were also subtyped as BRAF-like or RAS-like based on their cytomorphological features (22).

For data analysis, IBM SPSS Statistics 21.0 (IBM Corp., Armonk, NY, USA) was used. Continuous variables are presented as mean±standard deviation (SD) and median (range); categorical variables are expressed as percentages. The Mann-Whitney U test was used to evaluate numerical data such as age and tumor size and the chi-square test was used for all other comparisons. Statistical significance was defined as p<0.05.

RESULTS

Out of the 237 patients enrolled in this study, 160 (67.5%) were female and 77 (32.5%) were male. The mean age of the patients was 40.89±13.41 years, with a of 15 to 76 years. Thyroid nodules were detected in 131 (55.3%) patients, while no nodules were detected in 106 (44.7%) patients. Within the N-GD group, 95 (72.5%) patients were female, 36 (27.5%) were male, with a mean age of 45.52±13.37 years. In S-GD, 65 (61.3%) were female, and 41 (38.7%) were male, with a mean age was 35.18±11.09 years. The mean age was significantly higher in N-GD (p<0.001).

PTC was detected in 86 of 237 patients (36.3%). The PTC rates were 48.1% (63/131) and 21.7% (23/106) in N-GD and S-GD, respectively. The frequency of PTC was significantly higher in N-GD (Figure 1) (p<0.001). Tumor diameter ranged from 0.01 cm to 5.5 cm. Subcentimeter tumors (formerly known as papillary microcarcinomas) accounted for approximately 76.2% (48/63) of cases in N-GD and 82.6% (19/23) of cases in S-GD (p>0.05). Both N-GD and S-GD showed similar patterns in terms of PTC variants (invasive encapsulated follicular variant) or subtypes (classic, oncocytic, tall cell, and clear cell), bilaterality, multifocality, tumor localization, vascular invasion, lymphatic invasion, perineural invasion, parenchymal invasion, microscopic extrathyroidal extension, and cervical lymph node metastasis (p>0.05). Although not statistically significant, S-GD was enriched in BRAF-like PTCs, whereas N-GD had an equal distribution with respect to RAS and BRAF-like PTCs. The clinicopathological and histopathological features of the patients are summarized in Table 1.

Table 1 Clinical and histopathological characteristics in Graves disease with and without thyroid nodule.

	Nodular GD (n=131)

	Simple GD (n=106)

	p value

	
Age (years) (mean±SD)

	45.52±13.37

	35.18±11.09

	<0.001

	
Gender, n (%)

				
Female

	95 (59.4)

	65 (40.6)

	0.067

	
Male

	36 (46.8)

	41 (53.2)

		
PTC, n (%)

	63 (73.3)

	23 (26.7)

	<0.001

	
Tumor size (cm) (mean±SD)

	0.76 ± 0.90

	0.73 ± 0.99

	0.384

	
≤1 cm

	48 (71.6)

	19 (28.4)

	0.733

	
>1 cm

	15 (78.9)

	4 (21.1)

		
Subtypes/variants, n (%)

	
Follicular variant

	20 (74.1)

	7 (25.9)

	0.908

	
Classic subtype

	27 (67.5)

	13 (32.5)

	0.171

	
Oncocytic follicular variant

	6 (85.7)

	1 (14.3)

	0.669

	
Tall cell subtype

	7 (87.5)

	1 (12.5)

	0.676

	
Clear cell subtype

	3 (100)

	0 (0)

	0.561

	
Bilaterality, n (%)

	16 (84.2)

	3 (15.8)

	0.353

	
Multifocality, n (%)

	24 (70.6)

	10 (29.4)

	0.839

	
Tumor localization, n (%)

	
Right

	42 (77.8)

	12 (22.2)

	0.328

	
Left

	33 (73.3)

	12 (26.7)

	0.986

	
Isthmus

	4 (66.7)

	2 (33.3)

	0.656

	
Encapsulated, n (%)

				
Total

	16 (84.2)

	3 (15.8)

	0.353

	
Partial

	8 (88.9)

	1 (11.1)

	0.434

	
Vascular invasion, n (%)

	0 (0)

	1 (100)

	0.267

	
Lymphatic invasion,

n (%)

	8 (80)

	2 (20)

	0.999

	
Perineural invasion,

n (%)

	0 (0)

	2 (100)

	0.069

	
Parenchymal invasion, n (%)

	29 (65.9)

	15 (34.1)

	0.183

	
Extrathyroidal extension, n (%)

	2 (100)

	0 (0)

	0.999

	
Surgical margin intact, n (%)

	4 (66.7)

	2 (33.3)

	0.656

	
Cervical lymph node metastasis, n (%)

	7 (87.5)

	1 (12.5)

	0.668

	
Cervical lymph node dissection, n (%)

	14 (60.9)

	9 (39.1)

	0.211

	
GD: Graves disease, PTC: Papillary thyroid carcinoma.

Figure 1 Graves disease is characterized by diffuse hyperplasia (A). BRAF- and RAS-like papillary thyroid carcinomas identified in Graves disease (B,C).

DISCUSSION

The association between follicular cell-derived thyroid carcinoma and GD has been an area of interest in endocrine oncology. Several pathogenetic hypotheses have been considered. Thyroid-stimulating hormone (TSH) and potentially multiple other factors may be responsible for the development of thyroid cancer in GD (23).

TSHR-stimulating antibodies with strong agonistic activity to TSHR are produced in GD, and the resulting antibody-mediated TSH stimulation causes the production of thyroid hormones. These antibodies also play a role in the proliferation and activity of thyroid follicular cells by inducing a TSH-like effect. Morshed et al. demonstrated that TSH stimulated by autoantibodies activated cAMP, CREB, AKT, and PKC and induced FRTL-5 rat thyroid cell proliferation in cell cultures (24). These findings suggest that multiple mitogenic factors are likely involved in thyroid follicular cell activation and proliferation, and these factors may be responsible for promoting tumor growth, inducing invasion, and stimulating angiogenesis in partnership with other growth factors (24–28). In some instances, the extensive sampling of tumors may reveal subtle microscopic foci of PTCs (29).

The characteristic presentation of GD typically involves diffuse enlargement of the thyroid gland, although nodular presentation is also not uncommon. The frequency of thyroid nodules ranged from 15 to 50% of GD, depending on the detection methods used to identify the presence of synchronous nodular thyroid gland (palpation, ultrasonography, or scintigraphy) (6,8,14–17,20,30). Chen et al. observed a 1.37-fold higher incidence of thyroid cancer in a GD cohort than in a control cohort (10). Some thyroid carcinomas have been incidentally detected in GD patients undergoing thyroidectomy, while others have been identified in the pre-operative workup of N-GD. In some series, PTC incidence ranged from 6.8% (8/117) to 17% (8/48) in GD (31,32), whereas in other series a much higher incidence (>30%) was reported (6,33,34). Similarly, we noted a rate of 36.3% (86/237) in our cohort. The variability in malignancy rates across these series may be attributed to geographic variation, variations in the extent of gross specimen sampling and pathologist experience (29,35).

Former studies have indicated that the incidence of PTC is much higher (ranging from 17.1% to 69%) in patients with underlying thyroid nodules (6,18,19) compared to those without nodules. This observation has also been supported in a meta-analysis that showed thyroid carcinoma occurrence in almost five times more frequently in GD with synchronous thyroid nodules (8). Consistent with the former data, our series also showed a higher frequency of PTCs in N-GD (48.1%) compared to S-GD (21.7%).

The biological behavior difference of carcinoma observed in GD and euthyroid patients has also been area of debate in the literature. Some studies reported thyroid carcinoma in GD can be associated with aggressive biological behavior and a worse clinical outcome when compared to euthyroid patients with differentiated thyroid carcinoma (11,26,36–39). However, these results have not been widely supported in all former series (40–42). While the current study design precludes us to assess the biologic differences between GD-related PTCs and PTCs identified in euthyroid patients, we investigated differences in prognostic histopathological parameters (histological features including BRAF-like or RAS-like tumor subgrouping, vascular invasion, lymphatic invasion, perineural invasion, extrathyroidal extension, lymph node metastasis, etc.) in N-GD and S-GD groups. Although there was a slight difference in select histopathological variables between the two groups (such as lymph node metastasis and lymphatic invasion), no single variable showed a statistically significant difference (p>0.05).

Another important finding is GD-related PTCs were enriched in subcentimeter low-risk tumors with a prevalence that varies depending on the presence of the underlying nodular thyroid tissue. Patients with N-GD had a higher risk of thyroid malignancy, consistent with the findings identified in some former reported series (6,8,18,19). Although not statistically significant, S-GD was enriched in BRAF-like tumors, whereas N-GD had an equal distribution with respect to RAS and BRAF-like tumors (43). Considering the higher malignancy risk for N-GD patients, surgical intervention may be a favorable option for the clinical management. This approach enables an evaluation of the potential malignancy and also aids in risk stratification. While most GD-related PTCs are associated with a low-risk disease, individual risk stratification is still indicated irrespective to the tumor size since subcentimeter papillary thyroid carcinomas are required to be subtyped as per the 2022 WHO classification of thyroid neoplasms (22) and other adverse features (e.g., angioinvasion, high-grade features) should be recorded.

Conflict of Interest

The authors have no conflicts of interest to declare that are relevant to the content of this article

Funding

The authors did not receive support from any organization for the submitted work.

Ethics Approval

The study was approved by the Ondokuz Mayis University Faculty of Medicine, Medical Ethics Committee (IRB No: OMU KAEK 2019/431).

Availability of Data and Material

All data is kept with corresponding author (MK).

Code Availability

No custom code or software application was used during the preparation of the manuscript.

Consent to Participate

Informed consent was not required due to the retrospective design of the study.

Consent for Publication

All authors approved the final version and publication of the manuscript.

The authors would like to thank Hasan Bulut from the Department of Statistics for statistical analysis.

* This study was presented as a poster at the 29th European Congress of Pathology (ECP) in the Netherlands, 2017..
==== Refs
Biddinger PW Diagnostic Pathology and Molecular Genetics of the Thyroid Diffuse and Nodular Hyperplasia Nikiforov Y , Biddinger PW , Thompson LDR Lippincott Williams&Wilkins Philadelphia 2012
69 93
Jacobson D. L. , Gange S. J. , Rose N. R. , Graham N. M. Clin Immunol Immunopathol Epidemiology and estimated population burden of selected autoimmune diseases in the United States 09 1997
84 223 243 10.1006/clin.1997.4412 9281381
Tomer Yaron , Davies Terry F. Endocr Rev Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function 10 2003
24 694 717 10.1210/er.2002-0030
Yin Xiaoming , Latif Rauf , Bahn Rebecca , Tomer Yaron , Davies Terry F. Thyroid Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy 11 2008
18 1201 1206 10.1089/thy.2008.0098
Menconi Francesca , Marcocci Claudio , Marinò Michele Autoimmun Rev Diagnosis and classification of Graves' disease 2014
13 398 402 10.1016/j.autrev.2014.01.013 24424182
Wei Shuanzeng , Baloch Zubair W. , LiVolsi Virginia A. Endocr Pathol Thyroid carcinoma in patients with Graves' disease: an institutional experience 03 2015
26 48 53 10.1007/s12022-014-9343-6 25332114
Gerenova J. , Buysschaert M. , Burbure C. Y. de , Daumerie Ch Eur J Intern Med Prevalence of thyroid cancer in Graves' disease: a retrospective study of a cohort of 103 patients treated surgically 08 2003
14 321 325 10.1016/s0953-6205(03)00105-5 13678758
Staniforth Joy U. L. , Erdirimanne Senarath , Eslick Guy D. Int J Surg Thyroid carcinoma in Graves' disease: A meta-analysis 03 2016
27 118 125 10.1016/j.ijsu.2015.11.027 26626367
Pellegriti Gabriella , Mannarino Celestina , Russo Marco , Terranova Rosa , Marturano Ilenia , Vigneri Riccardo , Belfiore Antonino J Clin Endocrinol Metab Increased mortality in patients with differentiated thyroid cancer associated with Graves' disease 03 2013
98 1014 1021 10.1210/jc.2012-2843 23348395
Chen Yen-Kung , Lin Cheng-Li , Chang Yen-Jung , Cheng Fiona Tsui-Fen , Peng Chiao-Ling , Sung Fung-Chang , Cheng Ya-Hsin , Kao Chia-Hung Thyroid Cancer risk in patients with Graves' disease: a nationwide cohort study 07 2013
23 879 884 10.1089/thy.2012.0568 23421548
Kikuchi S. , Noguchi S. , Yamashita H. , Uchino S. , Kawamoto H. Br J Surg Prognosis of small thyroid cancer in patients with Graves' disease 04 2006
93 434 439 10.1002/bjs.5279 16523447
Lee Jandee , Nam Kee Hyun , Chung Woung Youn , Soh Euy-Young , Park Cheong Soo J Korean Med Sci Clinicopathologic features and treatment outcomes in differentiated thyroid carcinoma patients with concurrent Graves' disease 10 2008
23 796 801 10.3346/jkms.2008.23.5.796
Phitayakorn Roy , McHenry Christopher R. Am J Surg Incidental thyroid carcinoma in patients with Graves' disease 03 2008
195 292 297; discussion 297 10.1016/j.amjsurg.2007.12.006 18206132
Kraimps J. L. , Bouin-Pineau M. H. , Mathonnet M. , De Calan L. , Ronceray J. , Visset J. , Marechaud R. , Barbier J. Br J Surg Multicentre study of thyroid nodules in patients with Graves' disease 08 2000
87 1111 1113 10.1046/j.1365-2168.2000.01504.x 10931060
Cantalamessa L. , Baldini M. , Orsatti A. , Meroni L. , Amodei V. , Castagnone D. Arch Intern Med Thyroid nodules in Graves disease and the risk of thyroid carcinoma 08 1999
159 1705 1708 10.1001/archinte.159.15.1705 10448772
Kim Won Bae , Han Seong-Min , Kim Tae Yong , Nam-Goong Il Seong , Gong Gyungyub , Lee Ho Kyu , Hong Suck Joon , Shong Young Kee Clin Endocrinol (Oxf) Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease 06 2004
60 719 725 10.1111/j.1365-2265.2004.02043.x 15163336
Erbil Y. , Barbaros U. , Ozbey N. , Kapran Y. , Tükenmez M. , Bozbora A. , Ozarmağan S. J Laryngol Otol Graves' disease, with and without nodules, and the risk of thyroid carcinoma 03 2008
122 291 295 10.1017/S0022215107000448 17697433
Ergin Ahmet B. , Saralaya Sparsha , Olansky Leann Am J Otolaryngol Incidental papillary thyroid carcinoma: clinical characteristics and prognostic factors among patients with Graves' disease and euthyroid goiter, Cleveland Clinic experience 2014
35 784 790 10.1016/j.amjoto.2014.04.013 25128909
Mishra A. , Mishra S. K. J Postgrad Med Thyroid nodules in Graves' disease: implications in an endemically iodine deficient area 2001
47 244 247 11832639
Ren Meng , Wu Mu Chao , Shang Chang Zhen , Wang Xiao Yi , Zhang Jing Lu , Cheng Hua , Xu Ming Tong , Yan Li World J Surg Predictive factors of thyroid cancer in patients with Graves' disease 01 2014
38 80 87 10.1007/s00268-013-2287-z
Kahaly George J. , Bartalena Luigi , Hegedüs Lazlo , Leenhardt Laurence , Poppe Kris , Pearce Simon H. Eur Thyroid J 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism 08 2018
7 167 186 10.1159/000490384 30283735
Baloch Zubair W. , Asa Sylvia L. , Barletta Justine A. , Ghossein Ronald A. , Juhlin C. Christofer , Jung Chan Kwon , LiVolsi Virginia A. , Papotti Mauro G. , Sobrinho-Simões Manuel , Tallini Giovanni , Mete Ozgur Endocr Pathol Overview of the 2022 WHO Classification of Thyroid Neoplasms 03 2022
33 27 63 10.1007/s12022-022-09707-3 35288841
Chu Yu-De , Yeh Chau-Ting Cells The Molecular Function and Clinical Role of Thyroid Stimulating Hormone Receptor in Cancer Cells 07 2020
9 1730 1730 10.3390/cells9071730 32698392
Morshed Syed A. , Latif Rauf , Davies Terry F. Endocrinology Characterization of thyrotropin receptor antibody-induced signaling cascades 01 2009
150 519 529 10.1210/en.2008-0878
Rapoport B. , Chazenbalk G. D. , Jaume J. C. , McLachlan S. M. Endocr Rev The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies 12 1998
19 673 716 10.1210/edrv.19.6.0352
Belfiore A. , Garofalo M. R. , Giuffrida D. , Runello F. , Filetti S. , Fiumara A. , Ippolito O. , Vigneri R. J Clin Endocrinol Metab Increased aggressiveness of thyroid cancer in patients with Graves' disease 04 1990
70 830 835 10.1210/jcem-70-4-830 2180978
Pazaitou-Panayiotou K. , Michalakis K. , Paschke R. Horm Metab Res Thyroid cancer in patients with hyperthyroidism 04 2012
44 255 262 10.1055/s-0031-1299741 22334393
Filetti S. , Belfiore A. , Amir S. M. , Daniels G. H. , Ippolito O. , Vigneri R. , Ingbar S. H. N Engl J Med The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancer 03 1988
318 753 759 10.1056/NEJM198803243181206 3347223
Semerci Orhan , Gucer Hasan Endocr Pathol The Significance of Unsampled Microscopic Thyroid Carcinomas in Multinodular Goiter 03 2023
34 119 128 10.1007/s12022-022-09743-z 36527546
Aghini-Lombardi F. , Antonangeli L. , Martino E. , Vitti P. , Maccherini D. , Leoli F. , Rago T. , Grasso L. , Valeriano R. , Balestrieri A. , Pinchera A. J Clin Endocrinol Metab The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey 02 1999
84 561 566 10.1210/jcem.84.2.5508
Tamatea Jade A. U. , Tu'akoi Kelson , Conaglen John V. , Elston Marianne S. , Meyer-Rochow Goswin Y. ANZ J Surg Thyroid cancer in Graves' disease: is surgery the best treatment for Graves' disease? 04 2014
84 231 234 10.1111/j.1445-2197.2012.06233.x 22985335
Weber Kaare J. , Solorzano Carmen C. , Lee Jane K. , Gaffud Michael J. , Prinz Richard A. Am J Surg Thyroidectomy remains an effective treatment option for Graves' disease 03 2006
191 400 405 10.1016/j.amjsurg.2005.10.043 16490555
Boutzios Georgios , Vasileiadis Ioannis , Zapanti Evangelia , Charitoudis Georgios , Karakostas Efthimios , Ieromonachou Panagiotis , Karatzas Theodore Thyroid Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves' Disease 02 2014
24 347 354 10.1089/thy.2013.0133
Dayanan R. , Bilen A. , Demirci T. , Ciftel S. , Ciftel E. , Mercantepe F. , Onalan E. , Capoglu I. , Bilen H. Eur Rev Med Pharmacol Sci Investigation on the prevalence of thyroid cancer in Graves' patients in northeastern part of Turkey: is surgery a better option for patients with Graves' disease who develop antithyroid drug-related major adverse events? 05 2022
26 3562 3569 10.26355/eurrev_202205_28851 35647837
Katsakhyan Levon , Song Sharon , Lepe Marcos , Shojaei Hadi , Montone Kathleen T. , LiVolsi Virginia A. , Baloch Zubair W. Endocr Pathol Practice Paradigms Before and After Introduction of the Diagnosis-Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): an Institutional Experience 06 2020
31 174 181 10.1007/s12022-020-09614-5 32146581
Cappelli C. , Castellano M. , Braga M. , Gandossi E. , Pirola I. , De Martino E. , Agosti B. , Rosei E. Agabiti J Surg Oncol Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience 06 2007
95 555 560 10.1002/jso.20746 17226813
Pellegriti G. , Belfiore A. , Giuffrida D. , Lupo L. , Vigneri R. J Clin Endocrinol Metab Outcome of differentiated thyroid cancer in Graves' patients 08 1998
83 2805 2809 10.1210/jcem.83.8.4997 9709951
Stocker D. J. , Burch H. B. Minerva Endocrinol Thyroid cancer yield in patients with Graves' disease 09 2003
28 205 212 14605602
Song Yang , Fu Lijun , Wang Pu , Sun Ning , Qiu Xinguang , Li Jianhua , Zheng Shouhua , Ren Shuwei , Ding Xiaochong , Li Liwen , Du Junwei , Wang Chenyi , Jiao Zan , Zhao Wending Endocrine Effect of Graves' disease on the prognosis of differentiated thyroid carcinoma: a meta-analysis 03 2020
67 516 525 10.1007/s12020-019-02111-8 31637658
Yano Yukiko , Shibuya Hiroshi , Kitagawa Wataru , Nagahama Mitsuji , Sugino Kiminori , Ito Kunihiko , Ito Koichi Eur J Endocrinol Recent outcome of Graves' disease patients with papillary thyroid cancer 09 2007
157 325 329 10.1530/EJE-07-0136 17766715
Duh Quan-Yang Ann Surg Oncol Thyroid cancer in Graves disease: incidental cancer versus clinical cancer 04 2004
11 356 357 10.1245/ASO.2004.02.913 15070592
Hales I. B. , McElduff A. , Crummer P. , Clifton-Bligh P. , Delbridge L. , Hoschl R. , Poole A. , Reeve T. S. , Wilmshurst E. , Wiseman J. J Clin Endocrinol Metab Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer 09 1992
75 886 889 10.1210/jcem.75.3.1517381 1517381
Turchini John , Sioson Loretta , Clarkson Adele , Sheen Amy , Delbridge Leigh , Glover Anthony , Sywak Mark , Sidhu Stan , Gill Anthony J. Endocr Pathol The Presence of Typical "BRAFV600E-Like" Atypia in Papillary Thyroid Carcinoma is Highly Specific for the Presence of the BRAFV600E Mutation 03 2023
34 112 118 10.1007/s12022-022-09747-9 36709221
